机构：[1]Department of Medical Oncology, Shanghai Pulmonary Hospital, Shanghai 200433, China[2]Department of Medical Oncology, Hubei Cancer Hospital, Wuhan 430000, China[3]LTD Israeli-Georgian Medical Research Clinic ‘‘Helsicore’’, Tbilisi 0112, Georgia[4]Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara 06230, Turkey[5]Department of Pneumology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China[6]Department of Pneumology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China[7]Department of Thoracic Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China[8]Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou 221009, China[9]Clinical Research Department, Medical Center ‘‘Mriya Med-Service’’, Kryvyi Rih 50000, Ukraine[10]LTD ‘‘High Technology Hospital MedCenter’’, Batumi 6010, Georgia[11]Department of Medical Oncology, Jiamusi Cancer Hospital, Jiamusi 154007, China[12]Lung Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China四川大学华西医院[13]Department of Medical Oncology, Linyi Cancer Hospital, Linyi 276000, China[14]Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding 071000, China河北大学附属医院[15]Department of Medical Oncology, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China[16]Department of Medical Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China[17]Department of Oncology, Linyi People’s Hospital, Linyi 276002, China[18]LTD Institute of Clinical Oncology, Tbilisi 0159, Georgia[19]Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China[20]Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China[21]Department of Oncology, Jilin Cancer Hospital, Changchun 130012, China[22]Shanghai Henlius Biotech, Inc., Shanghai 200233, China[23]Department of Medical Oncology, Istinye University Faculty of Medicine, Istanbul 34010, Turkey
This work was funded by Shanghai Henlius Biotech, Inc. We would like to
acknowledge the patients who participated in the trial, their families, the principal
investigators, clinicians, study coordinators, and nurses. We thank the
clinical study team (Clinical Operations: Qiong Wang; Statistics: Yali Liu, Wenting
Qiu, Jiancheng Cheng) and Wenjie Zhang from Shanghai Henlius Biotech,
Inc., for their support in study execution, study design, data acquisition, statistical
analyses, and manuscript revisions. Medical writing support was provided
by JingYi Lee and Xinlei Yu of Parexel, and Shiqi Zhong and Chen Hu
of Shanghai Henlius Biotech, Inc., and funded by Shanghai Henlius
Biotech, Inc
第一作者机构：[1]Department of Medical Oncology, Shanghai Pulmonary Hospital, Shanghai 200433, China
通讯作者：
推荐引用方式(GB/T 7714)：
Caicun Zhou,Yanping Hu,Ekaterine Arkania,et al.A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)[J].CANCER CELL.2024,42(2):doi:10.1016/j.ccell.2023.12.004.
APA：
Caicun Zhou,Yanping Hu,Ekaterine Arkania,Saadettin Kilickap,Kejing Ying...&Jun Zhu.(2024).A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004).CANCER CELL,42,(2)
MLA：
Caicun Zhou,et al."A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)".CANCER CELL 42..2(2024)
医学